Skip to main content
Supriya Lifescience Limited logo

Supriya Lifescience Limited — Investor Relations & Filings

Ticker · SUPRIYA ISIN · INE07RO01027 LEI · 894500RBVJX1EOJP0Y02 BSE.NS Manufacturing
Open in API
Filings indexed 468 across all filing types
Latest filing 2024-01-31 Regulatory Filings
Country IN India
Listing BSE.NS SUPRIYA

About Supriya Lifescience Limited

https://www.supriyalifescience.com

Supriya Lifescience Limited is a research-driven manufacturer of Active Pharmaceutical Ingredients (APIs) with a focus on diverse therapeutic segments. The company specializes in the production of antihistamines, anti-allergics, vitamins, anesthetics, and anti-asthmatics. Its core product portfolio includes Chlorpheniramine Maleate, Ketamine Hydrochloride, and Salbutamol Sulphate, maintaining a significant global market share in these niche categories. Operating with a strong emphasis on backward integration, the firm ensures supply chain reliability and cost efficiency. The manufacturing infrastructure is compliant with international regulatory standards, including approvals from the USFDA, EDQM, and PMDA. Supriya Lifescience serves a broad international clientele across more than 100 countries, catering to both regulated and semi-regulated markets through its advanced R&D capabilities and commitment to quality excellence.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a notification dated January 31, 2024, informing stock exchanges and the public about an upcoming earnings call scheduled for February 8, 2024. It references the discussion of operational and financial performance for the quarter and nine months ended December 31, 2023. The document includes details such as the date and time of the call, management representatives who will participate, and dial-in information. It does not contain any actual financial data or results but serves as an announcement of the earnings call event. According to the classification rules, such notifications are classified as Call Transcript (CT) only if they contain the full transcript of the call. Since this is only an intimation of the earnings call, it is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not fit other categories. However, given the options and the nature of the document, the closest specific category is Call Transcript (CT) if the document were the transcript itself, but since it is only an announcement, it is Regulatory Filings (RNS).
2024-01-31 English
Board Meeting — SUPRIYA LIFESCIENCE LIMITED has informed the Exchange about Board Meeting to be held on 07-Feb-2024 to inter-alia consider and approve the Unaudited Financial results of the Company f…
Regulatory Filings
2024-01-30 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a letter dated January 30, 2024, addressed to stock exchanges (BSE and NSE) informing them of a forthcoming Board Meeting scheduled for February 7, 2024. The purpose of the meeting is to consider and approve the unaudited financial results for the quarter and nine months ended December 31, 2023. The letter also mentions the closure of the trading window in compliance with insider trading regulations. The document does not contain any financial data or results itself but is an announcement of an upcoming event related to financial reporting. The document length is 2523 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement informing the market about the board meeting and the upcoming financial results announcement, without containing the results or detailed financial information itself.
2024-01-30 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended December 31, 2023. It is a confirmation certificate from the Registrar and Share Transfer Agent regarding dematerialisation of securities and related compliance. The document is short (3563 characters) and primarily serves as a regulatory compliance certificate rather than a financial report or announcement of financial results. It does not contain financial statements or detailed financial data. It is not an announcement of a report but a compliance certificate under a specific SEBI regulation. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for regulatory compliance documents that do not fit other specific categories.
2024-01-08 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Supriya Lifesciences Limited received GMP certification from ANVISA Brazil. It is addressed to stock exchanges and mentions compliance with SEBI Listing Regulations. The content focuses on the certification achievement and its business implications, without any financial data, detailed report, or regulatory filing beyond the announcement itself. The document length is 4091 characters, which is relatively short and typical for a press release. There is no indication that this is a full financial report, audit report, or regulatory filing. It is an announcement of a corporate event related to certification, which does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is not a voting result, board change, or legal proceeding. Therefore, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements and compliance-related disclosures that do not fit other categories.
2024-01-05 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges notifying the closure of the trading window for insiders in compliance with insider trading regulations. It mentions the upcoming declaration of unaudited financial results for the quarter and nine months ended December 31, 2023, but does not contain any financial data or results itself. The document is short (2184 characters) and serves as an announcement related to regulatory compliance and trading restrictions rather than a financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such compliance and notification documents.
2023-12-28 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.